March MIMS update

We look at some of the recent changes to the medicines landscape, with new products, indications and contraindications New Products Nirsevimab (Beyfortus) is a recombinant neutralising human IgG1ĸ long-acting monoclonal antibody to the prefusion conformation of the respiratory syncytial virus (RSV) F protein which has been modified with a triple amino acid substitution (YTE) in